The filing confirms accelerated cash burn and reliance on equity financing. Watch for upcoming Q1 2026 results and updates on the proposed EG BioMed merger and SSMC acquisition, which could further dilute shareholders. The stock may face pressure as the market prices in the going concern risk.
Price Chart
Executive Summary
YD Bio's FY2025 annual report reveals a net loss of $8.3M on revenue of $597K, with operating expenses surging 236% to $5.4M due to R&D, G&A, and warrant liability changes. The company's going concern disclosure and accumulated deficit of $10.2M highlight severe cash burn, partially offset by the $13.2M PIPE raised in August 2025. Despite a 17% revenue increase, the loss widened 493%, and the core diagnostics business remains pre-revenue without FDA approval.
Key Facts
- Net loss of $8,311,316 for FY2025 vs. $1,411,559 loss in FY2024
- Revenue of $596,817, up 17% from $510,360, driven by pharmaceutical sales
- Going concern warning issued with accumulated deficit of $10,238,359
- Cash and cash equivalents of $6,007,615, down from $13.2M PIPE proceeds in August 2025
- Change in fair value of warrant liabilities of $3,168,091 contributed to loss
- CEO Dr. Ethan Shen beneficially owns 76.7% of outstanding shares
Financial Impact
Net loss of $8.3M vs. $1.4M prior year; operations consumed $6.6M in cash
Risk Factors
- Going concern risk without additional financing
- Substantial doubt about ability to fund operations beyond 12 months
- No FDA-approved products; reliance on LDT framework and partnerships
- Dilution from warrant exercises and potential equity raises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 18 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001213900-26-050282 |
| Document: ea028616001ex2-1.htm | 0001213900-26-050282 |
| Document: ea028616001ex4-15.htm | 0001213900-26-050282 |
| Document: ea028616001ex11-2.htm | 0001213900-26-050282 |
| Document: ea028616001ex11-1.htm | 0001213900-26-050282 |
| Document: ea028616001ex4-16.htm | 0001213900-26-050282 |
| Document: ea028616001ex97-1.htm | 0001213900-26-050282 |
| Document: ea028616001ex12-1.htm | 0001213900-26-050282 |
| Document: ea028616001ex12-2.htm | 0001213900-26-050282 |
| Document: ea028616001ex16-3.htm | 0001213900-26-050282 |
| Document: ea028616001ex13-2.htm | 0001213900-26-050282 |
| Document: ea028616001ex13-1.htm | 0001213900-26-050282 |
| Document: ea028616001ex15-2.htm | 0001213900-26-050282 |
| Document: ea028616001ex8-1.htm | 0001213900-26-050282 |
| Document: ea028616001ex16-1.htm | 0001213900-26-050282 |
| Document: ea028616001ex15-1.htm | 0001213900-26-050282 |
| Document: 0001213900-26-050282-index-headers.html | 0001213900-26-050282 |
| Document: 0001213900-26-050282-index.html | 0001213900-26-050282 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 1, 2026 21w ago | EFFECT | $0.7096 $0.3599 | ▼ −49.28% | ▼ −50.51% | — |
Apr 30, 2026 25w ago | 20-F | $0.7096 $0.2800 | ▲ +60.54% | ▲ +63.61% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers